Evidence map›Paper›PMID 42827123›Full record

ReviewEye (London, England)2026

Restorative and regenerative therapies for vision loss.

Nikolay Boychev, Jonathan R Soucy, Sally H Dang, Catherine T Tran, Alexis G Malkin, Vincent Yeung, Amy E Ross, Audrey E K Hutcheon, Levi N Kanu

Abstract readReview
PubMed Publisher
In one paragraph

Review in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nikolay BoychevDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA. nboychev@meei.harvard.edu.ORCID http://orcid.org/0000-0003-2674-0835
Jonathan R SoucyDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1236-1279
Sally H DangVision Center of Excellence, Defense Health Agency, Silver Spring, MD, USA.
Catherine T TranOptometry Service, Veterans Affairs Long Beach Healthcare System, Long Beach, CA, USA.ORCID http://orcid.org/0009-0007-0827-585X
Alexis G MalkinNECO Center for Eye Care, New England College of Optometry, Boston Medical Center, BU Eye Associates, Boston, MA, USA.
Vincent YeungDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA.
Amy E RossDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA.
Audrey E K HutcheonDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6088-7836
Levi N KanuDepartment of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Schepens Eye Research Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6428-4696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reversing blindness and restoring functional vision remains a central challenge in biomedical engineering. Advances in ocular prosthetics have enabled limited recovery of light perception, motion detection, and coarse object recognition through anterior segment devices such as keratoprostheses and through posterior segment interfaces including retinal, suprachoroidal, optic nerve, and cortical implants. Parallel progress in organ-on-a-chip systems and retinal organoids is providing increasingly sophisticated platforms for disease modelling and therapeutic development. Despite these advances, issues of long-term biocompatibility, signal fidelity, and surgical complexity continue to constrain clinical performance. Emerging approaches that combine stem cell-derived tissues, biofabrication, and hybrid bioelectronic constructs offer promising avenues for next-generation vision restoration, although current production remains limited to early-stage or small-scale systems. Effective integration of these technologies also requires structured vision-rehabilitation strategies to harness neuroplasticity and support functional adaptation. This review synthesises recent progress across prosthetic, rehabilitative, and regenerative domains and outlines key opportunities for future translational development.

Identifiers

PMID42827123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.